CO5271679A1 - PROTEASA INHIBITORS 7-14 MEMBERS - Google Patents
PROTEASA INHIBITORS 7-14 MEMBERSInfo
- Publication number
- CO5271679A1 CO5271679A1 CO00011383A CO00011383A CO5271679A1 CO 5271679 A1 CO5271679 A1 CO 5271679A1 CO 00011383 A CO00011383 A CO 00011383A CO 00011383 A CO00011383 A CO 00011383A CO 5271679 A1 CO5271679 A1 CO 5271679A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- het
- group
- nr2h
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/16—Eight-membered rings
- C07D313/18—Eight-membered rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto de Fórmula I:<EMI FILE="00011383_1" ID="1" IMF=JPEG >en la que: A es C(O) o CH(OH); R1 es <EMI FILE="00011383_2" ID="2" IMF=JPEG >R´ es seleccionado del grupo que consiste en H, alquilo C1-6, Ar-alquilo C0-6 o Het alquilo C0-6; R" es seleccionado del grupo que consiste en H, alquilo C1-6, Ar-alquilo C0-6 o Het alquilo C0-6; R"AND#39 es seleccionado del grupo que consiste en H, alquilo C1-6, cicloalquilo C3-6-alquilo C0-6, Ar-alquilo C0-6 o Het-alquilo C0-6; R2 es seleccionado del grupo que consiste en H, alquenilo C2-6, alquinilo C2-6, Het. Ar o alquilo C1-6 opcionalmente sustituido con 0R6, SR6, NR62, R6NC(O)OR5, CO2R6, CO2NR62, N(C=NH)NH2, Het o Ar; R3 es seleccionado del grupo que consiste en H, alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6, Het-alquilo C0-6, R4C(O)-, R4C(S)-, R4SO2-, R4OC(O)-, R4R7NC(O)-, R4R7NC(S)-, R7HNCH(R7)C(O)-, o R4OC(O)NR7CH(R7)C(O)-; R4 es seleccionado del grupo que consiste en alquilo C1-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 o Het-alquilo C0-6; R5 es seleccionado del grupo que consiste en H, alquilo C1-6, Ar-alquilo C0-6 o Het-alquilo C0-6;R6 y R7 son seleccionados del grupo que consiste en H, alquilo C1-6, Ar-alquilo C0-6 o Het-alquilo C0-6;M es seleccionado del grupo que consiste en: HC = CH, H2C-CH2, H(OR2)C-C(OR2)H, H(OR2)C-CH2, H(NR2H)C-C(NR2H)H, o H(OR2)C-C(NR2H)H, o H(NR2H)C-CH2; n es 1-7; L es 0-1;o sales, hidratos y solvatos farmacéuticamente aceptables de los mismos.A compound of Formula I: <EMI FILE = "00011383_1" ID = "1" MFI = JPEG> in which: A is C (O) or CH (OH); R1 is <EMI FILE = "00011383_2" ID = "2" IMF = JPEG> R 'is selected from the group consisting of H, C1-6 alkyl, Ar-C0-6 alkyl or Het C0-6 alkyl; R "is selected from the group consisting of H, C1-6 alkyl, Ar-C0-6 alkyl or Het C0-6 alkyl; R" AND # 39 is selected from the group consisting of H, C1-6 alkyl, C3 cycloalkyl -6-C0-6 alkyl, Ar-C0-6 alkyl or Het-C0-6 alkyl; R2 is selected from the group consisting of H, C2-6 alkenyl, C2-6 alkynyl, Het. Ar or C1-6 alkyl optionally substituted with 0R6, SR6, NR62, R6NC (O) OR5, CO2R6, CO2NR62, N (C = NH) NH2, Het or Ar; R3 is selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, R4C (O) -, R4C (S) - , R4SO2-, R4OC (O) -, R4R7NC (O) -, R4R7NC (S) -, R7HNCH (R7) C (O) -, or R4OC (O) NR7CH (R7) C (O) -; R4 is selected from the group consisting of C1-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl or Het-C0-6 alkyl; R5 is selected from the group consisting of H, C1-6 alkyl, Ar-C0-6 alkyl or Het-C0-6 alkyl; R6 and R7 are selected from the group consisting of H, C1-6 alkyl, Ar-C0 alkyl -6 or Het-C0-6 alkyl; M is selected from the group consisting of: HC = CH, H2C-CH2, H (OR2) CC (OR2) H, H (OR2) C-CH2, H (NR2H) CC (NR2H) H, or H (OR2) CC (NR2H) H, or H (NR2H) C-CH2; n is 1-7; L is 0-1; or pharmaceutically acceptable salts, hydrates and solvates thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12069999P | 1999-02-19 | 1999-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5271679A1 true CO5271679A1 (en) | 2003-04-30 |
Family
ID=22392011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00011383A CO5271679A1 (en) | 1999-02-19 | 2000-02-18 | PROTEASA INHIBITORS 7-14 MEMBERS |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1153022A4 (en) |
JP (1) | JP2002537297A (en) |
AU (1) | AU3235100A (en) |
CO (1) | CO5271679A1 (en) |
DZ (1) | DZ3083A1 (en) |
HK (1) | HK1042695A1 (en) |
PE (1) | PE20001486A1 (en) |
WO (1) | WO2000049011A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7168084B1 (en) | 1992-12-09 | 2007-01-23 | Sedna Patent Services, Llc | Method and apparatus for targeting virtual objects |
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001034599A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
EP1229914A4 (en) | 1999-11-10 | 2004-06-23 | Smithkline Beecham Corp | Protease inhibitors |
WO2001034600A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
NZ520588A (en) | 2000-03-21 | 2004-06-25 | Smithkline Beecham Corp | Protease inhibitors |
JP2004513942A (en) * | 2000-11-17 | 2004-05-13 | メディヴァー ユーケイ リミテッド | Cysteine protease inhibitor |
JP2004520439A (en) * | 2000-11-17 | 2004-07-08 | メディヴィル・アクチボラグ | Cysteine protease inhibitor |
DE502004001386D1 (en) * | 2003-05-27 | 2006-10-19 | Merck Patent Gmbh | Pyranderivative with exocyclic double bond |
ATE340836T1 (en) | 2003-05-27 | 2006-10-15 | Merck Patent Gmbh | PYRAND DERIVATIVES |
EP1757284A1 (en) * | 2005-08-25 | 2007-02-28 | Santhera Pharmaceuticals (Schweiz) AG | Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5021432A (en) * | 1988-04-26 | 1991-06-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzopyran compound and its pharmaceutical use |
CA2157412A1 (en) * | 1993-03-03 | 1994-09-15 | Julia Marie Heerding | Balanoids |
US5612370A (en) * | 1995-06-07 | 1997-03-18 | Bristol-Myers Squibb Company | Phenylglycine and phenylalaninen amido benzopyran derivatives |
AR013079A1 (en) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | SUBSTITUTED DERIVATIVES OF TETRAHIDROFURANO-3-ONAS, TETRAHIDROPIRANO-3- ONAS AND TETRAHIDROTIOFEN-3-ONAS, A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION OF A MEDICINAL PRODUCT USEFUL AS INTERMEDIATE PROTEIN INHIBITORS |
-
2000
- 2000-02-16 DZ DZ000030A patent/DZ3083A1/en active
- 2000-02-17 WO PCT/US2000/004133 patent/WO2000049011A1/en not_active Application Discontinuation
- 2000-02-17 JP JP2000599751A patent/JP2002537297A/en not_active Withdrawn
- 2000-02-17 EP EP00910222A patent/EP1153022A4/en not_active Withdrawn
- 2000-02-17 AU AU32351/00A patent/AU3235100A/en not_active Abandoned
- 2000-02-18 PE PE2000000128A patent/PE20001486A1/en not_active Application Discontinuation
- 2000-02-18 CO CO00011383A patent/CO5271679A1/en not_active Application Discontinuation
-
2002
- 2002-03-28 HK HK02102419.7A patent/HK1042695A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2002537297A (en) | 2002-11-05 |
EP1153022A1 (en) | 2001-11-14 |
AU3235100A (en) | 2000-09-04 |
WO2000049011A1 (en) | 2000-08-24 |
DZ3083A1 (en) | 2004-06-02 |
EP1153022A4 (en) | 2002-03-27 |
HK1042695A1 (en) | 2002-08-23 |
PE20001486A1 (en) | 2001-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5200785A1 (en) | THERAPEUTIC USE OF QUINAZOLINE | |
AR240929A2 (en) | N-pyridinsulphonyl-n<<'-pyridinyl and -triazinyl ureas: process for the preparation thereof, intermediates for exclusive use in said process and compositions that contain said ureas | |
DE59308619D1 (en) | GERMICIDE ACTIVE SUBSTANCE COMBINATIONS | |
CO5261616A1 (en) | NON-PEPTIDIC INHIBITORS OF THE CELLULAR UNION DEPENDENTS OF VLA-4 USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES | |
CO5550421A2 (en) | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASE | |
NZ511739A (en) | New esters derived from substituted phenyl-cyclohexyl compounds | |
NO20013379D0 (en) | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | |
RU2009102832A (en) | C-Phenyl-1-Tyloglucytols | |
CO5271679A1 (en) | PROTEASA INHIBITORS 7-14 MEMBERS | |
CO5251427A1 (en) | OXAZOLIDINONES THAT HAVE THE SULFOXIMINE FOTION | |
DE60112306D1 (en) | CONDENSED PYRAZINDION DERIVATIVES AS PDE5 INHIBITORS | |
CO5080791A1 (en) | PIPERIDINE DERIVATIVES THAT HAVE EFFECTS ON SYSTEMS WITH SEROTONIN | |
DK1189900T3 (en) | Heterocyclic aminopyrrolidine derivatives as melatonergic drugs | |
CO5261538A1 (en) | NEW ACIDS (AMINOPROPIL) METHYLPHOSPHINICS | |
CO5261527A1 (en) | ETERES OF THE BENZOIC ACID OF OXAZOLIDINONES THAT HAVE A SUBSTITUENT HYDROXYACETILEPIPERAZINE | |
DE60112960D1 (en) | CONDENSED PYRIDOINDOL DERIVATIVES | |
ATE333457T1 (en) | CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | |
DK1202954T3 (en) | Novel aminobenzophenones | |
CO5200762A1 (en) | PREPARATION OF PIPERIDIN-4-SUBSTITUTED WAVES | |
DK1204658T3 (en) | Benzofurylpiperazine-serotonin agonists | |
DE60122559D1 (en) | INDOLDERIVATE AS PDE5 INHIBITORS | |
ATE293111T1 (en) | CONDENSED PYRAZINEDIONE DERIVATIVES AS PDE INHIBITORS | |
DE60121048D1 (en) | PYRAZINOi1'2 ': 1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
CO5180541A1 (en) | PROTEASE INHIBITORS OF THE 1,3-DIAMINOCETONE TYPE WITH 8-14 MEMBER RING | |
CO5180536A1 (en) | CATEPSIN PROTEASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |